Feminizing hormone therapy

Feminizing hormone therapy, also known as gender-affirming hormone therapy, is a form of hormone therapy and gender transition for transgender women and non-binary individuals who are assigned male at birth but identify as female or feminine. This medical process involves the administration of estrogens and antiandrogens to induce physical changes in the body aligned with one's gender identity. The goal of feminizing hormone therapy is to reduce masculine characteristics and promote the development of feminine physical traits.

Indications

Feminizing hormone therapy is indicated for individuals diagnosed with gender dysphoria, a condition where there is a significant discrepancy between their assigned sex at birth and their experienced or expressed gender. This therapy is part of the transition process for those seeking to align their physical appearance with their gender identity.

Hormonal Medications

The primary medications used in feminizing hormone therapy include:

• Estrogens: These are the main hormones responsible for promoting female secondary sexual characteristics such as breast development, redistribution of body fat, and skin softening. Common forms include estradiol pills, patches, and injections.
• Antiandrogens: These medications reduce the effects of testosterone in the body, decreasing masculine features such as facial hair and deepening of the voice. Examples include spironolactone, finasteride, and cyproterone acetate.
• Progesterone: Some practitioners may add progesterone to support breast development and mood, although its use remains controversial and not universally endorsed.

Effects and Changes

Feminizing hormone therapy leads to various physical and emotional changes, which may include:

• Development of breast tissue
• Redistribution of body fat to hips and thighs
• Softening of skin
• Decrease in muscle mass
• Thinning and slowed growth of body and facial hair
• Reduced erections and changes in libido
• Possible fertility reduction

It is important to note that the extent and rate of changes vary among individuals and some effects may be irreversible.

Risks and Monitoring

While feminizing hormone therapy can significantly improve quality of life and psychological well-being, it also carries potential risks and side effects. These may include:

• Venous thromboembolism
• Cardiovascular disease
• Liver dysfunction
• Weight gain
• Infertility

Regular monitoring by healthcare providers is essential to manage these risks. Blood tests are typically performed to monitor hormone levels, liver function, and lipid profiles.

Access and Administration

Access to feminizing hormone therapy may vary depending on local laws and healthcare systems. In many cases, individuals are required to undergo a psychological assessment before starting therapy. Hormones should only be taken under the supervision of a qualified healthcare provider to ensure safety and effectiveness.

Conclusion

Feminizing hormone therapy is a critical component of the transition process for many transgender women and non-binary individuals, offering significant benefits in aligning one's physical appearance with their gender identity. However, it is essential to approach this therapy with a comprehensive understanding of the potential risks and to engage in ongoing medical supervision.

• 
  Estradiol levels with rectal administration of estradiol in women
• 
  Estradiol levels with oral versus sublingual estradiol in postmenopausal women
• 
  Testosterone levels as a function of estradiol levels during oral estradiol therapy in transgender women
• 
  Estradiol and testosterone levels with a single intramuscular injection of 320 mg polyestradiol phosphate in men
• 
  Testosterone levels with estradiol alone, estradiol plus spironolactone, and estradiol plus cyproterone acetate in transfeminine people
• 
  Feminizing hormone therapy